These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

796 related articles for article (PubMed ID: 24013647)

  • 1. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.
    Landewé R; Braun J; Deodhar A; Dougados M; Maksymowych WP; Mease PJ; Reveille JD; Rudwaleit M; van der Heijde D; Stach C; Hoepken B; Fichtner A; Coteur G; de Longueville M; Sieper J
    Ann Rheum Dis; 2014 Jan; 73(1):39-47. PubMed ID: 24013647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial.
    Sieper J; Landewé R; Rudwaleit M; van der Heijde D; Dougados M; Mease PJ; Braun J; Deodhar A; Kivitz A; Walsh J; Hoepken B; Nurminen T; Maksymowych WP
    Arthritis Rheumatol; 2015 Mar; 67(3):668-77. PubMed ID: 25470228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
    van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
    Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).
    Mease PJ; Fleischmann R; Deodhar AA; Wollenhaupt J; Khraishi M; Kielar D; Woltering F; Stach C; Hoepken B; Arledge T; van der Heijde D
    Ann Rheum Dis; 2014 Jan; 73(1):48-55. PubMed ID: 23942868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity within and outside the home in patients with axial spondyloarthritis, including nonradiographic axial spondyloarthritis and ankylosing spondylitis.
    Osterhaus JT; Purcaru O
    Arthritis Res Ther; 2014 Aug; 16(4):R164. PubMed ID: 25099160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritis.
    Furst DE; Shaikh SA; Greenwald M; Bennett B; Davies O; Luijtens K; Staelens F; Koetse W; Bertin P
    Arthritis Care Res (Hoboken); 2015 Feb; 67(2):151-60. PubMed ID: 25302624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
    Callhoff J; Sieper J; Weiß A; Zink A; Listing J
    Ann Rheum Dis; 2015 Jun; 74(6):1241-8. PubMed ID: 24718959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol.
    Maksymowych WP; Kumke T; Auteri SE; Hoepken B; Bauer L; Rudwaleit M
    Arthritis Res Ther; 2021 Oct; 23(1):274. PubMed ID: 34715908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction.
    Landewé RB; van der Heijde D; Dougados M; Baraliakos X; Van den Bosch FE; Gaffney K; Bauer L; Hoepken B; Davies OR; de Peyrecave N; Thomas K; Gensler LS
    Ann Rheum Dis; 2020 Jul; 79(7):920-928. PubMed ID: 32381562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study.
    van der Heijde D; Gensler LS; Maksymowych WP; Landewé R; Rudwaleit M; Bauer L; Kumke T; Kim M; Auteri SE; Hoepken B; Deodhar A
    RMD Open; 2022 Mar; 8(1):. PubMed ID: 35296532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial.
    van der Heijde D; Baraliakos X; Hermann KA; Landewé RBM; Machado PM; Maksymowych WP; Davies OR; de Peyrecave N; Hoepken B; Bauer L; Nurminen T; Braun J
    Ann Rheum Dis; 2018 May; 77(5):699-705. PubMed ID: 29343510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis).
    Kroon FP; van der Burg LR; Ramiro S; Landewé RB; Buchbinder R; Falzon L; van der Heijde D
    Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD010952. PubMed ID: 26186173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe.
    Baraliakos X; Witte T; De Clerck L; Frediani B; Collantes-Estévez E; Katsifis G; VanLunen B; Kleine E; Hoepken B; Bauer L; Goodson N
    Rheumatology (Oxford); 2021 Jan; 60(1):113-124. PubMed ID: 32584415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol.
    van der Heijde D; Fleischmann R; Wollenhaupt J; Deodhar A; Kielar D; Woltering F; Stach C; Hoepken B; Arledge T; Mease PJ
    Ann Rheum Dis; 2014 Jan; 73(1):233-7. PubMed ID: 23942869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvements in workplace and household productivity with certolizumab pegol treatment in axial spondyloarthritis: results to week 96 of a phase III study.
    van der Heijde D; Braun J; Rudwaleit M; Purcaru O; Kavanaugh AF
    RMD Open; 2018; 4(1):e000659. PubMed ID: 29670761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Certolizumab pegol for treating axial spondyloarthritis.
    Desmarais J; Beier S; Deodhar A
    Expert Opin Biol Ther; 2016 Aug; 16(8):1059-64. PubMed ID: 27366922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy.
    Marin J; Acosta Felquer ML; Soriano ER
    Open Access Rheumatol; 2018; 10():33-41. PubMed ID: 29765257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis.
    Rudwaleit M; Rosenbaum JT; Landewé R; Marzo-Ortega H; Sieper J; van der Heijde D; Davies O; Bartz H; Hoepken B; Nurminen T; Deodhar A
    Arthritis Care Res (Hoboken); 2016 Jun; 68(6):838-44. PubMed ID: 26815944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Certolizumab Pegol on Patient-Reported Outcomes in Patients With Axial Spondyloarthritis.
    Sieper J; Kivitz A; van Tubergen A; Deodhar A; Coteur G; Woltering F; Landewé R
    Arthritis Care Res (Hoboken); 2015 Oct; 67(10):1475-80. PubMed ID: 25832312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Certolizumab Pegol Efficacy in Patients With Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status: An Analysis From the C-axSpAnd Study.
    Robinson PC; Maksymowych WP; Gensler LS; Hall S; Rudwaleit M; Hoepken B; Bauer L; Kumke T; Kim M; de Peyrecave N; Deodhar A
    ACR Open Rheumatol; 2022 Sep; 4(9):794-801. PubMed ID: 35733363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.